176
Participants
Start Date
May 31, 2008
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
Ixabepilone
Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m\^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
Ixabepilone
Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
New York Oncology Hematology, P.C., Amsterdam
Interlakes Oncology & Hematology, P.C., Rochester
Maryland Oncology Hematology, P.A., Columbia
Alliance Hematology Oncology, Pa, Westminster
Oncology & Hematology Associates Of Southwest Virginia, Inc., Salem
Raleigh Hematology Oncology Associates, Raleigh
Regional Cancer Care, Durham
Cancer Centers Of The Carolinas, Greenville
Ocala Oncology Center, Ocala
Florida Cancer Institute, Hudson
Cancer Centers Of Florida, P.A, Ocoee
Birmingham Hematology & Oncology Associates Llc, Birmingham
Central Indiana Cancer Centers, Carmel
Hope Center, Terre Haute
Minnesota Oncology Hematology, P.A., Minneapolis
Cancer Care & Hematology Specialists Of Chicagoland, Niles
Arch Medical Services, Inc., St Louis
Kansas City Cancer Center, Llc, Kansas City
Missouri Cancer Associates, Columbia
Texas Oncology - Lake Vista Cancer Center, Lewisville
Texas Cancer Center - Sherman, Sherman
Texas Cancer Center Of Mesquite, Mesquite
Texas Cancer Center At Medical City, Dallas
Texas Oncology, Dallas
Texas Oncology/Methodist Charlton Cancer Ctr, Dallas
Baylor Sammons Cancer Ctr, Dallas
Texas Oncology Sammons Cancer Center, Dallas
Paris Regional Cancer Center Lab, Paris
Longview Cancer Center, Longview
Tyler Cancer Center, Tyler
Texas Oncology, Garland
Texas Cancer Center, Arlington
Texas Oncology, Bedord
Texas Oncology, Fort Worth
Texas Cancer Center, Denton
Texas Oncology Cancer Care And Research Center, Waco
Texas Oncology, Houston
Texas Oncology Cancer Center - Sugar Land, Sugar Land
Deke Slayton Cancer Center, Webster
Mamie Mcfaddin Ward Cancer Center Texas Oncology, Beaumont
South Texas Cancer Center, McAllen
Texas Oncology, Pa, Midland
Texas Oncology-Central Austin Cancer Center, Austin
Texas Oncology - Odessa, Odessa
Hematology Oncology Associates, Phoenix
Arizona Oncology Associates D.B.A. Hematology Oncology, Tucson
Northern Arizona Hematology & Oncology Associates, Sedona
New Mexico Cancer Care Associates, Santa Fe
Comprehensive Cancer Center Of Nevada, Henderson
Southwest Cancer Care, Murrieta
Puget Sound Cancer Centers, Edmonds
Puget Sound Cancer Centers, Seattle
Northwest Cancer Specialists, Pc, Vancouver
Yakima Valley Memorial Hospital/North Star Lodge, Yakima
Cancer Care Northwest, Spokane
Evergreen Hematology And Oncology, Spokane
Hematology-Oncology Assoc. Of Northern Nj, Pa, Morristown
Lead Sponsor
US Oncology Research
INDUSTRY
R-Pharm
INDUSTRY